Riverbridge Partners LLC Has $53.71 Million Stock Position in Repligen Corporation (NASDAQ:RGEN)

Riverbridge Partners LLC trimmed its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 7.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 422,102 shares of the biotechnology company's stock after selling 32,996 shares during the period. Riverbridge Partners LLC owned approximately 0.75% of Repligen worth $53,708,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Oppenheimer & Co. Inc. acquired a new stake in Repligen during the 4th quarter worth approximately $216,000. LPL Financial LLC raised its holdings in Repligen by 47.6% during the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after buying an additional 10,395 shares during the period. Signaturefd LLC raised its holdings in Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the period. US Bancorp DE raised its holdings in Repligen by 1.9% during the 4th quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock worth $1,471,000 after buying an additional 190 shares during the period. Finally, Zions Bancorporation N.A. raised its holdings in Repligen by 48.9% during the 4th quarter. Zions Bancorporation N.A. now owns 14,079 shares of the biotechnology company's stock worth $2,027,000 after buying an additional 4,626 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Up 1.1%

Shares of NASDAQ:RGEN traded up $1.26 during midday trading on Monday, hitting $120.11. The stock had a trading volume of 854,503 shares, compared to its average volume of 731,624. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The business's 50-day simple moving average is $128.57 and its 200-day simple moving average is $141.68. Repligen Corporation has a 12 month low of $102.97 and a 12 month high of $182.52. The company has a market cap of $6.75 billion, a P/E ratio of -266.91, a PEG ratio of 3.40 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period in the previous year, the business posted $0.28 earnings per share. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. On average, sell-side analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research analyst reports. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. Finally, Royal Bank Of Canada decreased their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.